

Prevention of Viral Infections after SOT: Vaccination and More

B.Salzberger

ESOMID eLibrary
© by author

Vaccination of SOT-recipients

- Which infections/vaccines to consider?
- Are vaccines effective in SOT-recipients?
- Which vaccines are safe (and which are not)?
- Should we monitor antibody titers?
- Is there a comprehensive framework/guideline?
- Other preventive measures

Vaccines to consider in SOT recipients

- Pediatric patients
 - All routine vaccines (which are safe?)
- Adults
 - Herpes virus infections: VZV
 - Respiratory infections: Influenza (Pertussis, Pneumococci)
 - Others: Hepatitis B, Hepatitis A, HPV

Waiting List- Opportunity for Vaccination

- SOT is only rarely performed for sudden organ function deterioration (eg fulminant hepatic failure)
- Waiting list: Opportunity for vaccination
 - Boosters, refills (eg diphtheria, tetanus, pertussis)
 - Hepatitis A/B, VZV
 - Pneumococcal, influenza vaccines
- Vaccines are more effective **before** SOT
 - Live-attenuated vaccines can be given up to 2 weeks before SOT

Hepatitis A

- Generally low risk of infection, high risk of complication, especially in liver disease
 - In a Korean outbreak 0,5% mortality or transplantation
 - Study from Taiwan: 1,7% mortality in hospitalized patients
- Vaccine safe in SOT recipients
- Immunogenicity low in SOT patients
 - Seroconversion 27% in kidney, 26 in liver transplant recipients with two doses

Hepatitis A

- While on waiting list:
 - Vaccinate non-immune individuals with two doses
- SOT recipient
 - Vaccinate non-immune individuals
 - Waning of antibodies rapid and common (loss of seroprotective levels in 60% of seroconverters after two years)
 - Open questions:
 - Optimal schedule two doses?
 - Monitor antibodies and revaccinate?

Hepatitis B

- Low risk of infection, high risk of complications and chronic infection in immunocompromised individuals, especially with a liver graft from a anti HBc +-donor
- Vaccine safe in SOT recipients
- Pretransplant seroconversion rates 27-40%, even with high dose schedules
- Posttransplant seroconversion rates 40-70 (only children) %

Hepatitis B

- **Waiting list**
 - Vaccinate seronegative individuals with high dose schedule (3x), monitor seroprotection, apply additional booster
 - Open question:
 - number of boosters maximally?
 - Monitoring schedule
- **SOT recipients**
 - Vaccinate seronegative individuals with high dose schedule
 - Open questions: as above

HPV

- Risk of HPV-associated tumors clearly elevated (SIR 2-3) in SOT recipients
- HPV vaccine is safe in SOT recipients, quadrivalent more effective, also prevents warts
- Seroconversion in adolescents (9-17yo) 100% after 3 doses of quadrivalent vaccine
- Seroconversion rates in young adults (18-35yo) 53-68% (for different, lower in lung tx, lower soon after tx and with high dose immunosuppression)

HPV

- **Waiting list**
 - Vaccinate 9-26 year old SOT candidates (M/F), nonavalent vaccine, 3 doses
 - Open question: Monitoring, booster, age boundaries
- **SOT recipients**
 - Vaccinate 9-26 year old SOT recipients (M/F), nonavalent vaccine, 3 doses
 - Open questions: as above

Influenza

- High risk of infection and complication
- Burden of disease still ill-defined in seasonal influenza
 - In pandemic influenza (pdm2009) high morbidity and mortality in several multicenter cohorts
- Influenza vaccine seroconversion rates generally lower than in immunocompetent patients
- No data for clinical efficacy in SOT recipients

Influenza

- **Waiting List**
 - Vaccinate all candidates yearly with inactivated vaccine (LAV only children, only pretransplant)
 - Open questions: optimal dose/adjuvant?
- **SOT recipients**
 - Vaccinate all yearly with inactivated vaccine
 - Open questions: as above

Influenza Vaccine: Two Doses?

- Study in 499 SOT(kidney, liver, heart,lung)-recipients >16yo, > 30d post-transplant
- Randomised to single dose or single+booster dose at 5 weeks
- Higher seroconversion rates in the PP-Group (not mITT) at short term and week 10 for all virus types (OR 1.3-2.2 for seroprotection to different numbers of antigens in multivariate analysis)
- Only 3 clinical events

Varizella Zoster Virus

- High risk of complications with primary VZV-infection
- Zoster incidence clearly elevated in SOT-recipients (HR 2-5)
- VZV-vaccine and Zoster-vaccine currently LAV

VZV

- **Waiting list**
 - Vaccinate non-immune individuals with VZV-vaccine up to 50yo
 - Vaccinate with Zoster-vaccine (>50yo)
 - Open question: Zoster prevention with Zoster-vaccine?
- **SOT**
 - Do not vaccinate: Live vaccine (although VZV-vaccine safety in small pediatric cohorts encouraging)